Biologics CMO: Industry Outlook and the Growing Pipeline

The recent years have portrayed the renaissance in the domain of biologics, as pharmaceutical industry has once again gained attention towards the production of bioproducts. In fact, in 2019, a total of 28 biopharmaceutical products (including monoclonal antibodies, recombinant proteins and gene therapy) were approved in the US. Further, over 8,000 biological pharmaceutical products are currently under clinical investigation, across the world.

The modification and innovation in the biologics CMO industry operations for the production of various biologics have side-lined some of the earlier concerns associated with them, such as rate of attrition of pipeline drugs / therapies, prolonged development timelines, complex molecular structure (which demand niche and specialized expertise), current facility limitations and capacity constraints, and safety and efficacy-related issues, and has led to manufacturing of high-quality biologics in a larger quantity. Although, the larger players have the necessary resources to develop in-house capabilities to cater to the complex requirements related to the biologics CMO market, the mid-sized and smaller players generally opt for outsourcing of such operations.

Service Providers Offering Biologics CMO Services

Over 220 industry players are actively involved in the biologics CMO services market. The biologics CMO industry is presently highly fragmented, featuring the presence of small companies (30%), mid-sized players (47%), large firms (15%) and very large firms (8%). Some of well-established players engaged in this domain include (in alphabetical order) AbbVie Contract Manufacturing, Almac, FUJIFILM Diosynth Biotechnologies, GlaxoSmithKline (GSK), Lonza, Sandoz and Sanofi CEPiA.

Biopharma contract manufacturing industry list of firms by Roots Analysis

Recent Developments in the Biologics CMO Market

Since 2015, partnership activity within the biologics CMO domain has increased with an annualized growth rate of 7.9%. Manufacturing agreements have captured a substantial share in the partnerships related to biopharmaceutical contract manufacturing, during the period of 2015-2020.This was followed by product development and manufacturing agreements, which have captured a significant share of the partnerships inked in this domain. Further the domain has witnessed some consolidation during the period of 2016-202. We were able to identify the key value drivers, such as geographical consolidation, geographical expansion, capability expansion, capacity expansion and access to new technology behind the various acquisitions reported during the given time period. Majority (44%) of the acquisitions in the biologics CMO industry were focused on capability expansions, followed by geographical consolidation and geographical expansion (24%), each. Further, most of the expansions (44%) initiated within this domain were for the establishment of a new facility, followed by initiatives carried out for expansion of existing facilities (24%).

Biopharma contract manufacturing industry partnership analysis distribution by biologics type and partnership models by Roots Analysis

Capacity with the Companies – Enough to Meet the Demand?

The current manufacturing capacity installed by biologics contract manufacturing organizations is evenly distributed across different scale of operations. In addition, around 92% of the capacity belongs to large and very large biologics CDMO. Further, CMOs based in North America (29%), Europe (36%), and Asia-Pacific (35%) have comparable biomanufacturing capacity. This can be attributed to the inherent technical, regulatory and financial superiority of the aforementioned regions.

Biopharma contract manufacturing industry global capacity analysis by Roots Analysis

Likely Growth of the Biologics CMO Market

The biologics contract manufacturing market is anticipated to grow at an annualized rate of approximately 11%, as the drug developers are anticipated to continue to outsource their manufacturing services in mid to long term. At present, close to 90% of the total revenues are generated from commercialized biologics. Further, it is worth mentioning that the CMO market for biologics in North America and Europe are anticipated to capture 75% share of the market, by 2030.

Biopharma contract manufacturing industry landscape various trends by Roots analysis

With outsourcing being increasingly accepted as a viable and beneficial business model within the biopharmaceutical industry, we anticipate the biologics manufacturing services market to grow at a steady pace in the coming years.

For more details, you can also download the SAMPLE REPORT on biologics CMO by Roots Analysis.

Check out our new Reports

Roots Analysis – Research Insights

One Comment